{
  "schemaVersion" : 2,
  "registerId" : "F2014L00008",
  "instrumentNumber" : "9/2014",
  "citation" : "Statement of Principles concerning dermatomyositis No. 9 of 2014",
  "conditionName" : "dermatomyositis",
  "effectiveFrom" : "2014-01-15",
  "standardOfProof" : "Reasonable Hypothesis",
  "icdCodes" : [ ],
  "onsetFactors" : [ {
    "paragraph" : "6(a)",
    "text" : "being treated with a drug of the statin class for a continuous period of\r\nat least the two months before the clinical onset of dermatomyositis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(b)",
    "text" : "being treated with D-penicillamine for a continuous period of at least\r\nthe six weeks before the clinical onset of dermatomyositis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(c)",
    "text" : "for amyopathic dermatomyositis only, being treated with hydroxyurea\r\nfor a continuous period of at least the six months before the clinical\r\nonset of dermatomyositis",
    "definedTerms" : [ ],
    "conditionVariant" : {
      "name" : "amyopathic dermatomyositis",
      "variantFactors" : [ ]
    }
  }, {
    "paragraph" : "6(d)",
    "text" : "being treated with a drug which is associated in the individual with:\r\n(i) the development of dermatomyositis during drug therapy; and\r\neither\r\n(ii) the improvement of dermatomyositis within two months of\r\ndiscontinuing or tapering drug therapy; or\r\n(iii) the redevelopment of dermatomyositis on rechallenge with the\r\nsame drug;\r\nwhere treatment with the drug continued for at least the one month\r\nbefore the clinical onset of dermatomyositis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(e)",
    "text" : "having a malignant neoplasm, other than non-melanotic malignant\r\nneoplasm of the skin, within five years of the clinical onset of\r\ndermatomyositis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(f)",
    "text" : "having a specified viral infection within the three months before the\r\nclinical onset of dermatomyositis",
    "definedTerms" : [ {
      "term" : "a specified viral infection",
      "definition" : "means:\n(a) a coxsackie B virus infection;\n(b) an echovirus infection;\n(c) human immunodeficiency virus infection;\n(d) human T-cell lymphotropic virus type-1 infection; or\n(e) parvovirus B19 infection"
    } ]
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "6(g)",
    "text" : "being treated with a drug of the statin class for a continuous period of\r\nat least the two months before the clinical worsening of\r\ndermatomyositis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(h)",
    "text" : "being treated with D-penicillamine for a continuous period of at least\r\nthe six weeks before the clinical worsening of dermatomyositis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(i)",
    "text" : "for amyopathic dermatomyositis only, being treated with hydroxyurea\r\nfor a continuous period of at least the six months before the clinical\r\nworsening of dermatomyositis",
    "definedTerms" : [ ],
    "conditionVariant" : {
      "name" : "amyopathic dermatomyositis",
      "variantFactors" : [ ]
    }
  }, {
    "paragraph" : "6(j)",
    "text" : "being treated with a drug which is associated in the individual with:\r\n(i) the worsening of dermatomyositis during drug therapy; and\r\neither\r\n(ii) the improvement of dermatomyositis within two months of\r\ndiscontinuing or tapering drug therapy; or\r\n(iii) the worsening of dermatomyositis on rechallenge with the same\r\ndrug;\r\nwhere treatment with the drug continued for at least the one month\r\nbefore the clinical worsening of dermatomyositis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "6(k)",
    "text" : "having a specified viral infection within the three months before the\r\nclinical worsening of dermatomyositis",
    "definedTerms" : [ {
      "term" : "a specified viral infection",
      "definition" : "means:\n(a) a coxsackie B virus infection;\n(b) an echovirus infection;\n(c) human immunodeficiency virus infection;\n(d) human T-cell lymphotropic virus type-1 infection; or\n(e) parvovirus B19 infection"
    } ]
  }, {
    "paragraph" : "6(l)",
    "text" : "inability to obtain appropriate clinical management for\r\ndermatomyositis",
    "definedTerms" : [ ]
  } ]
}